View today's Lilama 3 JSC stock price and latest LM3 news and analysis. Create real-time notifications to follow any changes in the live stock price.
Reston, VA—A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission ...
A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results